Compounds > triazoles
Page last updated: 2024-08-24

triazoles and Thyroid Cancer, Anaplastic

triazoles has been researched along with Thyroid Cancer, Anaplastic in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cheng, SY; Copland, JA; Enomoto, K; Meltzer, P; Park, S; Qi, J; Willingham, MC; Zhao, L; Zhu, X; Zhu, YJ1
Baloglu, E; Ding, LW; Doan, NB; Ganesan, TS; Garg, M; Kanojia, D; Kauffman, M; Koeffler, HP; Mayakonda, A; Nagare, RP; S, S; Sadhanandhan, B; Said, JW; Shacham, S; Suresh, S1
Allegri, L; Baldan, F; Conzatti, K; Damante, G; Filetti, S; Mio, C; Rosignolo, F; Russo, D; Sponziello, M1
Chen, KY; Fagin, JA; Ghossein, R; Knauf, JA; Luckett, KA; Socci, ND; Voza, F1

Other Studies

4 other study(ies) available for triazoles and Thyroid Cancer, Anaplastic

ArticleYear
Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer.
    The Journal of clinical endocrinology and metabolism, 2017, 07-01, Volume: 102, Issue:7

    Topics: Animals; Antineoplastic Agents; Azepines; Cell Cycle; Cell Cycle Proteins; Cell Proliferation; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Genes, myc; Humans; Mice, Nude; Molecular Targeted Therapy; Neoplasm Invasiveness; Proto-Oncogene Proteins c-myc; Thyroid Carcinoma, Anaplastic; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2017
Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin.
    Scientific reports, 2017, 08-29, Volume: 7, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Disease Models, Animal; Doxorubicin; Exportin 1 Protein; Heterografts; Humans; Hydrazines; Karyopherins; Models, Biological; Neoplasm Transplantation; Receptors, Cytoplasmic and Nuclear; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Treatment Outcome; Triazoles; Tumor Cells, Cultured

2017
BET bromodomain inhibitor JQ1 modulates microRNA expression in thyroid cancer cells.
    Oncology reports, 2018, Volume: 39, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Azepines; Benzodiazepines; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 4 or More Rings; Humans; MicroRNAs; Phosphorylation; STAT3 Transcription Factor; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Triazoles

2018
Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers.
    The Journal of clinical investigation, 2018, 08-31, Volume: 128, Issue:9

    Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Cell Line, Tumor; Coumarins; Crizotinib; Disease Models, Animal; Drug Resistance, Neoplasm; Genes, p53; Humans; Indoles; MAP Kinase Signaling System; Mice; Mice, Transgenic; Mutation, Missense; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-met; Pyrazines; Sulfonamides; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Triazoles

2018